#AstraZeneca could be just months away from #FDA approval of a new #bladdercancer indication for its #PDL1inhibitor #Imfinzi, which is viewed as key to meeting its sales ambitions for the drug.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#AstraZeneca could be just months away from #FDA approval of a new #bladdercancer indication for its #PDL1inhibitor #Imfinzi, which is viewed as key to meeting its sales ambitions for the drug.